Back

Predicting Cardiovascular Risk in Patients with Prostate Cancer Receiving Abiraterone or Enzalutamide by Using Machine Learning

31 August 2025 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Cardio-oncology challenges Organisation of a Cardio-Oncology Service ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Dong-Yi Chen

Chang Gung Memorial Hospital Tapei, Taipei (Taiwan)

4 More presentations in this session

Presentation thumbnail
MyD-88/NLRP-3 inhibition by dapagliflozin protects against anthracycline and trastuzumab cardiotoxicity in preclinical models
Doctor N. Maurea (Naples, IT)
Abstract Slides Video
Presentation thumbnail
Biomarker and imaging characterisation of inflammatory atheroma in patients receiving immunotherapy and angiogenesis inhibitors (BIOCAPRI): a prospective study using positron emission tomography
Doctor S. Rankin (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Surveillance of left ventricular function among asymptomatic cancer survivors
Doctor C. Soh (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Cardiovascular risk profiling in allogenic hematopoietic stem cell transplantation survivors
Mr M. Mutti (Basel, CH)
Abstract Slides Video

Access the full session

Session thumbnail
Cardio-oncology challenges

The Event

Event poster

ESC Congress 2025

31 August 2025 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Adverse cardiovascular events in patients with cancer: a biomarker-enhanced clinical risk score
thumbnail
Congress Session
Risk prediction and treatment options in cardio-oncology
thumbnail
Congress Presentation
Artificial intelligence-based prediction of mortality, bleeding, and ischaemic events in cancer patients with acute coronary syndrome: A modelling study in the UK and Switzerland

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources